Welcome to our dedicated page for Beta Bionics SEC filings (Ticker: BBNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Beta Bionics, Inc. (Nasdaq: BBNX) provides access to the company’s official U.S. Securities and Exchange Commission disclosures. As a commercial-stage medical device company focused on the iLet Bionic Pancreas for insulin-requiring people with diabetes, Beta Bionics uses its filings to report financial results, operational metrics, and significant corporate events.
Investors can review current reports on Form 8-K, which the company uses to announce quarterly financial results and other material information. Recent 8-K filings reference press releases detailing net sales, gross margin, operating expenses, net loss, cash and investment balances, and non-GAAP measures such as adjusted EBITDA, along with reconciliations to the most directly comparable GAAP measures.
Filings also describe operational indicators that are central to Beta Bionics’ business, including installed customer base, new patient starts, and the mix of reimbursement between the Durable Medical Equipment channel and the Pharmacy Benefit Plan channel. These disclosures help readers understand how the iLet Bionic Pancreas is being adopted and reimbursed in practice.
In addition, the company has filed 8-Ks to furnish investor and analyst presentations and to summarize “real-world” iLet data. These materials discuss changes from baseline HbA1c to glucose management indicator, hypoglycemia metrics, and outcomes for users transitioning from multiple daily injections or competitive hybrid-closed loop systems, as well as analyses of usage patterns such as “fully-closed loop” operation.
Through its registration of common stock on the Nasdaq Global Market under the symbol BBNX, Beta Bionics is subject to ongoing reporting obligations. On this page, AI-powered tools can assist by summarizing lengthy filings, highlighting key figures and definitions, and helping readers navigate topics such as non-GAAP metrics, risk factor discussions, and descriptions of clinical and real-world data included in exhibits.
For anyone researching BBNX, the SEC filings page is a primary source for understanding the company’s reported financial condition, regulatory communications, and the detailed context behind its press releases and investor materials.
Soleus Capital-affiliated funds and Guy Levy filed an amended Schedule 13G reporting their beneficial ownership of Beta Bionics, Inc. common stock. As of the share count in the issuer’s Form 10-Q, Soleus Capital Management, L.P. and Soleus GP, LLC each report beneficial ownership of 2,503,778 shares, or 5.7% of the company’s common stock. Guy Levy reports beneficial ownership of 2,534,565 shares, or 5.8%, including 30,787 shares over which he has sole voting and dispositive power and the balance on a shared basis through the Soleus funds. Several Soleus entities and Mr. Levy expressly disclaim beneficial ownership of shares held by the funds except for purposes of Section 13(d), and they certify the holdings are not for the purpose of changing or influencing control of Beta Bionics.
Wellington Hadley Harbor Aggregator IV, L.P. reports that it no longer beneficially owns any shares of Beta Bionics, Inc. common stock. The amended Schedule 13G shows 0 shares beneficially owned, representing 0.0% of the class, with no sole or shared voting or dispositive power.
The filing notes that any securities previously held were not acquired or held for the purpose of changing or influencing control of Beta Bionics. Wellington certifies this change in ownership status as of 12/31/2025, formally confirming it is now below the 5% reporting threshold.
Beta Bionics, Inc. (BBNX)12/31/2025, Wellington Management Group LLP, Wellington Group Holdings LLP, and Wellington Investment Advisors Holdings LLP each report 0.00 shares of Beta Bionics common stock, representing 0.0% of the outstanding class, with no sole or shared voting or dispositive power.
The filing explains that any Beta Bionics shares covered by this schedule are owned of record by clients of various Wellington investment advisers, and no single client is known to hold more than five percent of the common stock. Wellington also certifies that any securities were acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of Beta Bionics.
Beta Bionics, Inc. received an updated Schedule 13G/A from Farallon-affiliated investors and Zone Healthcare Holdings, LLC. The filing reports Zone Healthcare Holdings and Farallon Capital Management, L.L.C. each beneficially owning 3,277,220 common shares, or 7.4% of the company.
Farallon’s individual reporting persons, including multiple senior investment professionals, are each reported as beneficial owners of 4,379,920 shares, representing 9.9% of the common stock. The amendment records governance changes: effective December 31, 2025, Richard B. Fried, Rajiv A. Patel, and William Seybold ceased to be beneficial owners, while effective January 1, 2026, Avner A. Husen became a deemed beneficial owner through his new management roles.
The group files under Rule 13d-1(c) and certifies the shares were not acquired to change or influence control of Beta Bionics.
Beta Bionics reported that it received a warning letter from the U.S. FDA on January 29, 2026 following an inspection of its Irvine, California facility conducted in June 2025. The FDA cited deficiencies in the company’s responses to a prior Form 483 and highlighted non-conformities in its quality system, medical device reporting, and correction and removal processes.
The letter does not currently limit Beta Bionics’ ability to manufacture, market, or distribute products, or to seek FDA 510(k) clearance for new products. The company has begun corrective actions, is preparing a written response, and plans ongoing updates to the FDA, but notes that additional regulatory action is possible until issues are resolved. Beta Bionics states it does not expect this warning letter to materially affect its previously disclosed guidance to launch commercialization of Mint by the end of 2027.
Beta Bionics, Inc. director Michel Gerard reported receiving an award of 3,997 shares of common stock on 01/13/2026. The filing shows this as an automatic acquisition at a price of $0 per share, representing a restricted stock unit grant under the company’s 2025 Equity Incentive Plan. Following this award, Gerard beneficially owns 16,544 shares of Beta Bionics common stock in direct form.
Beta Bionics, Inc. director Sean Carney reported a stock-based award. On 01/13/2026, he acquired 3,997 shares of common stock at a price of $0, described as a restricted stock unit award granted under the company’s 2025 Equity Incentive Plan. After this grant, he beneficially owned 15,244 shares of Beta Bionics common stock, held directly.
Beta Bionics, Inc. director Maria Palasis reported receiving a grant of 3,997 shares of common stock on January 13, 2026. The transaction is coded as an acquisition at a price of $0 per share and is described as a restricted stock unit award granted under the company’s 2025 Equity Incentive Plan. Following this award, Palasis beneficially owns 12,432 shares of Beta Bionics common stock, held in direct ownership.
Beta Bionics, Inc. director Christy Jones reported an equity award on a Form 4. On January 13, 2026, Jones acquired 3,997 shares of common stock with a transaction code "A," indicating an award rather than an open-market purchase, at a stated price of $0 per share.
The footnote explains this represents a restricted stock unit award granted under the company’s 2025 Equity Incentive Plan. Following this grant, Jones beneficially owns 15,244 shares of Beta Bionics common stock in direct ownership.
Beta Bionics, Inc. director Adam Lezack reported an equity award of 3,997 shares of common stock. The Form 4 shows that on January 13, 2026, he acquired 3,997 shares at a price of $0 per share, reflecting a grant rather than an open-market purchase. A footnote explains that this represents a restricted stock unit award granted under the company’s 2025 Equity Incentive Plan. Following this grant, Lezack beneficially owns 12,432 shares of Beta Bionics common stock, held directly.